ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,447,218, issued on Oct. 21.
"Radioconjugates directed to MHC-complexed antigens in cancer" was invented by Dale L Ludwig (Rockaway, N.J.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Radionuclide-labeled soluble biologics directed against peptide presenting Major Histocompatibility Complexes (pMHCs), and methods for treating cancers using the biologics are provided. Soluble biologics include recombinant T-cell receptor proteins (rTCR) and TCR-antibody mimics that specifically bind to pMHCs. The soluble biologics may further include a heavy chain of IgG1, IgG2, IgG4, or variants thereof. The radioisotopes used to label the soluble biologic may include a...